Presbia PLC announced that it has treated over 50% of subjects in the second stage enrollment of its pivotal study. The company received FDA approval to commence the second stage of its pivotal study in February, and continues enrollment of subjects at eleven investigational sites across the United States. Subjects treated as a part of stage one of the pivotal study are being actively monitored.